Items Tagged ‘Non-Hodgkin’s Lymphoma’

August 9th, 2017

Acalabrutinib granted Breakthrough Therapy Designation for the Treatment of Mantle Cell Lymphoma

By

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Acalabrutinib is a highly-selective, potent Bruton tyrosine kinase (BTK) inhibitor being evaluated for the treatment of multiple B-cell cancers. The Breakthrough Therapy Designation […]

View full entry

Tags: Acalabrutinib, Bruton tyrosine kinase, mantle cell lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


August 2nd, 2017

Pediatric MATCH Trial to Test Targeted Drugs in Childhood Cancers

By

Today investigators at the National Cancer Institute (NCI) and the Children’s Oncology Group (COG) announced the opening of enrollment for a unique precision medicine clinical trial. NCI-COG Pediatric Molecular Analysis for Therapy Choice (Pediatric MATCH) is a nationwide trial to explore whether targeted therapies can be effective for children and adolescents with solid tumors that […]

View full entry

Tags: Brain Cancer, brain tumors, children with solid tumors, histiocytoses, News, non-Hodgkin lymphomas, Non-Hodgkin's Lymphoma, Pediatric MATCH trial, Precision Cancer Medicine, targeted therapy


July 25th, 2017

Chimeric Antigen Receptor (CAR) T-cell Immunotherapy – Crafting a Better T Cell for Immunotherapy

By

Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult B-cell Acute Lymphoblastic Leukemia.  CAR-T also shows promise in ALL, CLL, other B-cell malignancies, and other cancers. In CAR T-cell therapy, a patents immune systems T-cells are collected and reprogrammed in the laboratory to recognize and […]

View full entry

Tags: all, CAR, chimeric antigen receptor, CLL, News, nhl, Non-Hodgkin's Lymphoma, T-cell Immunotherapy


July 12th, 2017

Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL

By

Recommendation based on review of CTL019 r/r B-cell ALL development program, including the pivotal Phase II global ELIANA trial  A Biologics License Application (BLA) for this indication is under FDA priority review; if approved, CTL019 could become first CAR-T cell therapy available  Positive ODAC recommendation is latest milestone for CTL019 program that started through collaboration […]

View full entry

Tags: car-t immunotherapy, Leukemia, Lymphoma, News, Non-Hodgkin's Lymphoma


May 4th, 2017

Kite Pharma Updates Results of CAR-T cell therapy in Aggressive Non-Hodgkin Lymphoma

By

Results from the ZUMA-1 trial of axicabtagene ciloleucel (KTE-C19) in patients with chemorefractory aggressive non-Hodgkin lymphoma (NHL) were updated recently at the American Society of Hematology Annual Meeting in San Diego, California.  Overall 76% of patients with Diffuse Large B-Cell Lymphoma (DLBCL) responded to treatment, 47% achieving a complete remissions (CR). About axicabtagene ciloleucel Axicabtagene […]

View full entry

Tags: CAR T, HD, HNL, immunotherapy, Lymphoma, News, nhl, Non-Hodgkin's Lymphoma


February 7th, 2017

Imbruvica® is approved by FDA for Marginal Zone Lymphoma

By

The U.S. Food and Drug Administration (FDA) has approved Imbruvica® (ibrutinib) for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. These data were recently presented at the 58th Annual American Society of Hematology Meeting in December 2016. About Marginal Zone Lymphoma […]

View full entry

Tags: ibrutinib, imbruvica, Marginal zone lymphoma, News, nhl, Non-Hodgkin's Lymphoma, precision medicine


December 15th, 2016

Gazyva® Improves Outcomes Compared to Rituxan® in Untreated Follicular Lymphoma

By

Treatment including the targeted agent Gazyva (obinutuzumab) delays cancer progression for a longer period of time than treatment with Rituxan (rituximab) among patients with follicular lymphoma who have not received prior therapy. These results were recently presented at a plenary session of the 2016 annual meeting of the American Society of Hematology (ASH). Follicular lymphoma […]

View full entry

Tags: ASH 2016, B-cells, FL, Follicular Lymphoma, GALLIUM trial, Gazyva, News, Non-Hodgkin's Lymphoma, obinutuzumab, rituxan, rituxumab


December 1st, 2016

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions

By

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring transfusions. These results were recently published in the New England Journal of Medicine. Many patients with cancer require red blood cell transfusions, either in response to the disease itself, or […]

View full entry

Tags: Blood transfusions, Hodgkin's Lymphoma, Leukemia, long-term, Multiple Myeloma, Myeloproliferative Neoplasms MPN, News, Non-Hodgkin's Lymphoma, short-term, storage


August 16th, 2016

Opdivo® Highly Effective for Some Patients with Lymphomas

By

The immunotherapeutic agent, Opdivo® (nivolumab), appears to provide long-lasting anti-cancer activity among some patients who have received extensive prior therapy for both B- and T-cell lymphomas. These results were recently published in the Journal of Clinical Oncology. Lymphomas are a type of cancer that arise in immune cells. There are two main types of immune […]

View full entry

Tags: diffuse large B-cell lymphoma, Follicular Lymphoma, Lymphoma, News, nivolumab, Non-Hodgkin's Lymphoma, opdivo, peripheral T-cell lymphoma, T-Cell Non-Hodgkin's Lymphoma


June 20th, 2016

CAR Therapy Effective in Advanced Lymphoma

By

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types of lymphomas. This type of treatment is continuing to produce impressive results, and is demonstrating effectiveness in several different types […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, asco, CAR, CAR T, chimeric antigen receptor, Follicular Lymphoma, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Leukemia, Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma


June 8th, 2016

Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in Follicular Lymphoma

By

Genentech, announced positive results from the pivotal Phase III GALLIUM study in people with previously untreated follicular lymphoma, the most common type of indolent (slow-growing) non-Hodgkin’s lymphoma (iNHL). The study compared Gazyva® (obinutuzumab) plus chemotherapy (CHOP, CVP or bendamustine) followed by Gazyva alone, head-to-head with Rituxan® (rituximab) plus chemotherapy followed by Rituxan alone. Results from […]

View full entry

Tags: Follicular Lymphoma, GALLIUM study, Gazyva, iNHL, News, nhl, Non-Hodgkin's Lymphoma, non-Hodgkin’s, rituxan, rituximab


March 30th, 2016

Defitelio® Approved for Life-Threatening Complication of Stem Cell Transplant

By

The United States Food and Drug Administration (FDA) has approved Defitelio® (defibrotide sodium) for the treatment of hepatic veno-occlusive disease (VOD) following a stem cell transplant. Defitelio is the first approved treatment for severe hepatic VOD. Hepatic VOD is a rare, but life-threatening complication that can occur following chemotherapy and a stem cell transplant (SCT) […]

View full entry

Tags: Chemotherapy, chemotherpay, hepatic VOC, Hodgkin's Lymphoma, HSCT, Leukemia, Lymphoma, Multiple Myeloma, News, Non-Hodgkin's Lymphoma, Stem Cell Transplant


February 24th, 2015

FDA Approves New Indication for Ibrutinib in Waldenström’s Macroglobulinemia

By

The US Food and Drug Administration (FDA) today expanded the approved use of Imbruvica® (ibrutinib) for patients with Waldenström’s macroglobulinemia, a rare type of B-cell lymphoma. Imbruvica® is the first therapy indicated specifically for Waldenström’s macroglobulinemia and previously received Breakthrough Therapy designation for this use. A type of non-Hodgkin lymphoma, Waldenström’s macroglobulinemia usually gets worse […]

View full entry

Tags: b-cell lymphoma, Breakthrough Therapy, ibrutinib, imbruvica, Indolent/Low Grade Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma, Waldenström’s macroglobulinemia


January 19th, 2015

FDA Grants Fast Track Designation to SGX301 for First-Line Treatment of Cutaneous T-Cell Lymphoma

By

The U. S. Food and Drug Administration has granted Fast Track designation the synthetic hypericin (SGX301) development program for the first-line treatment of cutaneous T-cell lymphoma. Fast Track designation from the FDA is reserved for drugs that demonstrate the potential to address an unmet medical need for a serious or life-threatening condition. SGX301 previously received […]

View full entry

Tags: cutaneous lymphoma, hypericin, News, Non-Hodgkin's Lymphoma, photodynamic therapy, sgx301, T-Cell Non-Hodgkin's Lymphoma


December 17th, 2014

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment

By

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft function due to their need for HIV medications. Results from the clinical trial, presented at the American Society of Hematology […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Follicular Lymphoma, General HIV Related Cancers, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, hiv, hiv cancer, HIV Related Cancers, Indolent/Low Grade Non-Hodgkin's Lymphoma, Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, nhl